The effects of vildagliptin compared with metformin on vascular endothelial function and metabolic parameters: a randomized, controlled trial (Sapporo Athero-Incretin Study 3)

Table 3 Relationship between the changes in FMD and other metabolic parameters pre- and post-treatment with vildagliptin or high-dose metformin

Variables	R	p value for the Spearman’s rank-correction	R	p value for the Spearman’s rank-correction
Medication	Vilda		High met
BMI	0.038	0.803	0.013	0.932
HbA1c	− 0.131	0.386	− 0.053	0.735
cSBP	− 0.069	0.651	0.050	0.751
Proinsulin/IRI ratio	− 0.060	0.694	− 0.046	0.770
LDL-cholesterol	− 0.249	0.095	0.101	0.521
ApoB/ApoA1 ratio	− 0.326	0.026	− 0.069	0.659
Adiponectin	0.049	0.746	0.124	0.432

FMD flow-mediated dilation, BMI body mass index, cSBP centric systolic blood pressure, IRI immunoreactive insulin, ApoB apolipoprotein B, ApoA1 apolipoprotein A1, BAP biological antioxidant potential

ISSN: 1475-2840